Why 2022 will be a record year for cell and gene therapy | Life Sciences Insights - March 2022

Heralding an encouraging new era of innovative technologies within the life sciences sector with long-term benefits and curative potential, Cell and Gene Therapy (CGT) has been seen as the ‘future’ of medicine for many years. We are now closer than ever to that future becoming the present.

We remain optimistic regarding the ever-growing technologies within the cell and gene therapy sector and believe the area will revolutionise the treatments of disease.

Our latest Life Sciences Insights report from finnCap Research considers the increased appetite of both VCs and the public markets in this sub-sector, strong M&A activity from large Pharma, disruptive therapies ready to shift current treatment paradigms and a therapy and technology pipeline that is now coming of age, all against the backdrop of the best year on record for potential approvals.

Download our research below.